



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



NAGS siRNA (m): sc-149805

BACKGROUND

The function of the urea cycle is to remove excess nitrogen from the body. Six distinct enzymes comprise the urea cycle, and urea cycle disorders (UCD) are a direct results of deficiency in any one of those enzymes. N-acetylglutamate synthase (NAGS) catalyzes the conversion of N-acetylglutamate (NAG) from glutamate and acetylcoenzyme A. NAG is an obligatory activator of carbamylphosphate I (CPSI), the first and rate limiting enzyme of ureagenesis. Therefore, deficiency of NAGS results in severe hyperammonemia. 21 mutations have been described in humans, 10 of which are associated with acute neonatal hyperammonemia, and the remainder found in patients with late onset disease. Treatment with N-carbamylglutamate (NCG) can ameliorate hyperammonemia for inherited and secondary NAGS deficiency. Expression of NAGS occurs in the liver, small intestine and kidney.

REFERENCES

1. Caldovic, L., Morizono, H., Gracia Panglao, M., Gallegos, R., Yu, X., Shi, D., Malamy, M.H., Allewell, N.M. and Tuchman, M. 2002. Cloning and expression of the human N-acetylglutamate synthase gene. *Biochem. Biophys. Res. Commun.* 299: 581-586.
2. Häberle, J., Schmidt, E., Pauli, S., Kreuder, J.G., Plecko, B., Galler, A., Wermuth, B., Harms, E. and Koch, H.G. 2003. Mutation analysis in patients with N-acetylglutamate synthase deficiency. *Hum. Mutat.* 21: 593-597.
3. Morizono, H., Caldovic, L., Shi, D. and Tuchman, M. 2004. Mammalian N-acetylglutamate synthase. *Mol. Genet. Metab.* 81: S4-S11.
4. Caldovic, L., Lopez, G.Y., Haskins, N., Panglao, M., Shi, D., Morizono, H. and Tuchman, M. 2006. Biochemical properties of recombinant human and mouse N-acetylglutamate synthase. *Mol. Genet. Metab.* 87: 226-232.
5. Caldovic, L., Morizono, H. and Tuchman, M. 2007. Mutations and polymorphisms in the human N-acetylglutamate synthase (NAGS) gene. *Hum. Mutat.* 28: 754-759.
6. Nordenström, A., Halldin, M., Hallberg, B. and Alm, J. 2007. A trial with N-carbamylglutamate may not detect all patients with NAGS deficiency and neonatal onset. *J. Inher. Metab. Dis.* 30: 400.
7. Deignan, J.L., Cederbaum, S.D. and Grody, W.W. 2008. Contrasting features of urea cycle disorders in human patients and knockout mouse models. *Mol. Genet. Metab.* 93: 7-14.
8. Tuchman, M., Caldovic, L., Daikhin, Y., Horyn, O., Nissim, I., Nissim, I., Korson, M., Burton, B. and Yudkoff, M. 2008. N-carbamylglutamate markedly enhances ureagenesis in N-acetylglutamate deficiency and propionic acidemia as measured by isotopic incorporation and blood biomarkers. *Pediatr. Res.* 64: 213-217.

CHROMOSOMAL LOCATION

Genetic locus: Nags (mouse) mapping to 11 D.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

PRODUCT

NAGS siRNA (m) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see NAGS shRNA Plasmid (m): sc-149805-SH and NAGS shRNA (m) Lentiviral Particles: sc-149805-V as alternate gene silencing products.

For independent verification of NAGS (m) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-149805A, sc-149805B and sc-149805C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNases and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

NAGS siRNA (m) is recommended for the inhibition of NAGS expression in mouse cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor NAGS gene expression knockdown using RT-PCR Primer: NAGS (m)-PR: sc-149805-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.